

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Genscript Biotech Corporation**

**金斯瑞生物科技股份有限公司\***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1548)**

**POLL RESULTS OF EXTRAORDINARY GENERAL MEETING  
HELD ON 21 DECEMBER 2017**

At the extraordinary general meeting (the “**EGM**”) of Genscript Biotech Corporation (the “**Company**”) held on 21 December 2017, the proposed resolutions put to the vote have been taken by way of poll, as set out in the notice of EGM dated 3 December 2017.

As at the date of the EGM, the total number of issued shares of the Company was 1,732,865,498 shares of US\$0.001 each, which was the total number of shares entitling the holder to attend and vote on the resolutions at the EGM. There were no shares entitling the holder to attend and abstain from voting in favour of the resolutions at the EGM as set out in Rule 13.40 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) nor any shares of holders required under the Listing Rules to abstain from voting at the EGM.

The Company’s branch share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer at the EGM for the purpose of vote-taking. The poll results in respect of the resolutions proposed at the EGM were as follows:

ORDINARY RESOLUTIONS		No. of Votes (%)	
		For	Against
1.	To approve the proposed adoption of the Subsidiary Share Option Scheme (as defined in the circular of the Company dated 3 December 2017)	951,511,034 (97.902844%)	20,382,118 (2.097156%)

As more than 50% of votes were casted in favour of the above ordinary resolutions, the above ordinary resolutions were approved by the shareholders of the Company.

By order of the Board  
**Genscript Biotech Corporation**  
**Zhang Fangliang**  
*Chairman and Chief Executive Officer*

Hong Kong  
21 December 2017

*As at the date of this announcement, the executive Directors are Dr. Zhang Fangliang, Ms. Wang Ye and Mr. Meng Jiange; the non-executive Directors are Dr. Wang Luquan, Mr. Huang Zuie-Chin and Mr. Pan Yuexin; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian and Ms. Zhang Min.*

\* *For identification purposes only*